Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Sigilon Therapeutics Inc. is managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners and 4 distinct art units. This spread suggests that the company's intellectual property covers several different sub-sectors within the biotech field, requiring a strategy that accounts for various examination styles. The presence of 4 distinct art units indicates that the portfolio is being reviewed across multiple specialized groups at the patent office.
STEVENS, MARK V is the busiest examiner for this portfolio, currently handling 2 pending office actions. This makes STEVENS, MARK V the examiner managing the highest number of actions for the company, as the remaining 4 actions are split among the other 4 examiners. This concentration suggests that this specific examiner's perspective will be particularly influential for these pending biotechnology matters. Practitioners should focus on the specific preferences of STEVENS, MARK V while also maintaining distinct approaches for the other 4 examiners involved in the prosecution of these 6 actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEVENS, MARK V | 2 | 65.5% | +41.6% |
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
| WEIDNER, ADAM M | 1 | 63.5% | +33.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17598154 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | WILSON, MICHAEL C | 215d overdue |
| 18274125 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE | STEVENS, MARK V | — |
| 18274123 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES | CANELLA, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17598154 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | WILSON, MICHAEL C | 215d overdue |
| 17784972 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | CHANDRAKUMAR, NIZAL S | 29d overdue |
| 18705759 | COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS | NATARAJAN, MEERA | — |
| 18274125 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE | STEVENS, MARK V | — |
| 18274123 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES | CANELLA, KAREN A | — |
| 18019664 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | STEVENS, MARK V | — |
| 16651892 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | WEIDNER, ADAM M | — |
| Art Unit | Apps |
|---|---|
| 1613 | 2 |
| 1643 | 1 |
| 1625 | 1 |
| 1638 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705759 | COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS | NATARAJAN, MEERA | — | §103 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18274125 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE | STEVENS, MARK V | 1613 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18274123 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES | CANELLA, KAREN A | 1643 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18019664 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | STEVENS, MARK V | 1613 | §102§103§112DP | Non-Final OA | — | Pending | Feb 03, 2023 |
| 17784972 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103DP | Final Rejection | 29d overdue | Pending | Jun 13, 2022 |
| 17598154 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | 215d overdue | Pending | Sep 24, 2021 |
| 16651892 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | WEIDNER, ADAM M | 1675 | §103Other | Final Rejection | — | Pending | Mar 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial